Cellosaurus 8505C (CVCL_1054)

Cell line name 8505C
Synonyms 8505c
Accession CVCL_1054
Resource Identification Initiative To cite this cell line use: 8505C (RRID:CVCL_1054)
Comments Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Doubling time: ~30-40 hours (DSMZ); 36 hours (ECACC).
Microsatellite instability: Stable (MSS) (Sanger).
Sequence variation: TP53 p.Arg248Gly (PubMed=23162534).
Omics: Deep exome analysis.
Omics: DNA methylation analysis.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Misspelling: 8509C; In Cosmic 1132598.
Disease Thyroid gland undifferentiated (anaplastic) carcinoma (NCIt: C3878)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Sex of cell Female
Category Cancer cell line
STR profile Source(s): Cosmic-CLP; DSMZ; ECACC; JCRB; PubMed=18713817; PubMed=21868764; PubMed=25877200; RCB; TKG

Markers:
AmelogeninX
CSF1PO12,13
D13S31713
D16S53912
D18S5116
D19S43313,14
D21S1128,32.2
D2S133817,24
D3S135816,17
D5S81810,11
D7S82010
D8S117910,13
FGA23
Penta D9,10
Penta E12,15
TH016,9 (Cosmic-CLP; DSMZ; ECACC; JCRB; PubMed=21868764; RCB; TKG)
6 (PubMed=25877200)
TPOX10,11 (Cosmic-CLP; DSMZ; RCB; TKG)
11 (ECACC; JCRB; PubMed=21868764; PubMed=25877200)
vWA17,19
Publications

PubMed=21566963; DOI=10.3892/ijo.4.3.583
Ito T., Seyama T., Hayashi Y., Hayashi T., Dohi K., Mizuno T., Iwamoto K., Tsuyama N., Nakamura N., Akiyama M.
Establishment of 2 human thyroid-carcinoma cell-lines (8305C, 8505C) bearing p53 gene-mutations.
Int. J. Oncol. 4:583-586(1994)

PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D
Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T., Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M., Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.
Screening the p53 status of human cell lines using a yeast functional assay.
Mol. Carcinog. 19:243-253(1997)

PubMed=16924234; DOI=10.1038/sj.onc.1209899
Yu W., Imoto I., Inoue J., Onda M., Emi M., Inazawa J.
A novel amplification target, DUSP26, promotes anaplastic thyroid cancer cell growth by inhibiting p38 MAPK activity.
Oncogene 26:1178-1187(2007)

PubMed=17725429; DOI=10.1089/thy.2007.0097
Meireles A.M., Preto A., Rocha A.S., Rebocho A.P., Maximo V., Pereira-Castro I., Moreira S., Feijao T., Botelho T., Marques R., Trovisco V., Cirnes L., Alves C., Velho S., Soares P., Sobrinho-Simoes M.
Molecular and genotypic characterization of human thyroid follicular cell carcinoma-derived cell lines.
Thyroid 17:707-715(2007)

PubMed=17804723; DOI=10.1158/0008-5472.CAN-06-4026
van Staveren W.C.G., Solis D.W., Delys L., Duprez L., Andry G., Franc B., Thomas G., Libert F., Dumont J.E., Detours V., Maenhaut C.
Human thyroid tumor cell lines derived from different tumor types present a common dedifferentiated phenotype.
Cancer Res. 67:8113-8120(2007)

PubMed=18713817; DOI=10.1210/jc.2008-1102
Schweppe R.E., Klopper J.P., Korch C., Pugazhenthi U., Benezra M., Knauf J.A., Fagin J.A., Marlow L.A., Copland J.A., Smallridge R.C., Haugen B.R.
Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification.
J. Clin. Endocrinol. Metab. 93:4331-4341(2008)

PubMed=19087340; DOI=10.1186/1471-2407-8-371
Ribeiro F.R., Meireles A.M., Rocha A.S., Teixeira M.R.
Conventional and molecular cytogenetics of human non-medullary thyroid carcinoma: characterization of eight cell line models and review of the literature on clinical samples.
BMC Cancer 8:371-371(2008)

PubMed=21868764; DOI=10.1158/1078-0432.CCR-11-0690
Zhao M., Sano D., Pickering C.R., Jasser S.A., Henderson Y.C., Clayman G.L., Sturgis E.M., Ow T.J., Lotan R., Carey T.E., Sacks P.G., Grandis J.R., Sidransky D., Heldin N.-E., Myers J.N.
Assembly and initial characterization of a panel of 85 genomically validated cell lines from diverse head and neck tumor sites.
Clin. Cancer Res. 17:7248-7264(2011)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=23162534; DOI=10.3389/fendo.2012.00133
Saiselet M., Floor S., Tarabichi M., Dom G., Hebrant A., van Staveren W.C.G., Maenhaut C.
Thyroid cancer cell lines: an overview.
Front. Endocrinol. 3:133-133(2012)

PubMed=23833040; DOI=10.1210/jc.2013-2383
Landa I., Ganly I., Chan T.A., Mitsutake N., Matsuse M., Ibrahimpasic T., Ghossein R.A., Fagin J.A.
Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease.
J. Clin. Endocrinol. Metab. 98:E1562-E1566(2013)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

Cross-references
Cell line collections AddexBio; C0025002/19
DSMZ; ACC-219
ECACC; 94090184
JCRB; JCRB0826
RCB; RCB2103
TKG; TKG 0439
Cell line databases/resources CLDB; cl135
CLDB; cl136
CCLE; 8505C_THYROID
CGH-DB; 54-1
Cosmic-CLP; 924102
GDSC; 924102
LINCS_LDP; LCL-1686
Ontologies BTO; BTO:0005550
CLO; CLO_0001513
CLO; CLO_0050951
Biological sample resources BioSample; SAMN01821611
BioSample; SAMN03470935
BioSample; SAMN03472518
BioSample; SAMN03473379
Chemistry resources ChEMBL-Cells; CHEMBL3308353
ChEMBL-Targets; CHEMBL1075387
Gene expression databases GEO; GSM886847
GEO; GSM887911
GEO; GSM1669574
Polymorphism and mutation databases Cosmic; 889489
Cosmic; 891256
Cosmic; 922365
Cosmic; 924102
Cosmic; 1084283
Cosmic; 1132598
Cosmic; 1152114
Cosmic; 1162837
Cosmic; 1239959
Cosmic; 2036694
Cosmic; 2054105
Cosmic; 2613248